| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1538 | 2021 |
| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1480 | 2018 |
| Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’study HJN Andreyev, AR Norman, D Cunningham, J Oates, BR Dix, ... British journal of cancer 85 (5), 692-696, 2001 | 1081 | 2001 |
| Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study HJN Andreyev, AR Norman, PA Clarke, D Cunningham, JR Oates JNCI: Journal of the National Cancer Institute 90 (9), 675-684, 1998 | 957 | 1998 |
| The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective … AJ Folkes, K Ahmadi, WK Alderton, S Alix, SJ Baker, G Box, ... Journal of medicinal chemistry 51 (18), 5522-5532, 2008 | 848 | 2008 |
| Discovery of small molecule cancer drugs: successes, challenges and opportunities S Hoelder, PA Clarke, P Workman Molecular oncology 6 (2), 155-176, 2012 | 687 | 2012 |
| BCL-2 antisense therapy in patients with non-Hodgkin lymphoma A Webb, D Cunningham, FEA Cotter, PA Clarke, F Di Stefano, P Ross, ... The Lancet 349 (9059), 1137-1141, 1997 | 650 | 1997 |
| Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1 B Panaretou, G Siligardi, P Meyer, A Maloney, JK Sullivan, S Singh, ... Molecular cell 10 (6), 1307-1318, 2002 | 646 | 2002 |
| Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma JS Waters, A Webb, D Cunningham, PA Clarke, F Raynaud, F di Stefano, ... Journal of Clinical Oncology 18 (9), 1812-1823, 2000 | 640 | 2000 |
| Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases FI Raynaud, S Eccles, PA Clarke, A Hayes, B Nutley, S Alix, A Henley, ... Cancer research 67 (12), 5840-5850, 2007 | 440 | 2007 |
| Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma … ME Hill, KA MacLennan, DC Cunningham, B Vaughan Hudson, M Burke, ... | 395 | 1996 |
| Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis I Hostein, D Robertson, F DiStefano, P Workman, P Andrew Clarke Cancer research 61 (10), 4003-4009, 2001 | 394 | 2001 |
| Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis MV Powers, PA Clarke, P Workman Cancer cell 14 (3), 250-262, 2008 | 376 | 2008 |
| Inhibitors of cyclin-dependent kinases as cancer therapeutics SR Whittaker, A Mallinger, P Workman, PA Clarke Pharmacology & therapeutics 173, 83-105, 2017 | 332 | 2017 |
| Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 FI Raynaud, SA Eccles, S Patel, S Alix, G Box, I Chuckowree, A Folkes, ... Molecular cancer therapeutics 8 (7), 1725-1738, 2009 | 330 | 2009 |
| Drugging the PI3 kinome: from chemical tools to drugs in the clinic P Workman, PA Clarke, FI Raynaud, RLM van Montfort Cancer research 70 (6), 2146-2157, 2010 | 326 | 2010 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 317 | 2021 |
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ... Clinical cancer research 21 (1), 77-86, 2015 | 311 | 2015 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 306* | 2022 |
| Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance D Gonzalez de Castro, PA Clarke, B Al‐Lazikani, P Workman Clinical Pharmacology & Therapeutics 93 (3), 252-259, 2013 | 301 | 2013 |
